Rockefeller Capital Management
NBIX icon

Rockefeller Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Rockefeller Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.2M Buy
282,097
+777
+0.3% +$103K 0.07% 280
2025
Q4 		$39.9M Buy
281,320
+87,372
+45% +$12.7M 0.07% 261
2025
Q3 		$27.2M Buy
193,948
+80,719
+71% +$10.9M 0.05% 331
2025
Q2 		$14.2M Buy
113,229
+91,630
+424% +$10.5M 0.03% 494
2025
Q1 		$2.39M Buy
21,599
+1,729
+9% +$219K 0.01% 968
2024
Q4 		$2.71M Buy
19,870
+549
+3% +$67.9K 0.01% 906
2024
Q3 		$2.23M Buy
19,321
+44
+0.2% +$6.03K 0.01% 957
2024
Q2 		$2.65M Buy
+19,277
New +$2.64M 0.01% 882
2023
Q3 		– Sell
-6,945
Closed -$655K – 1710
2023
Q2 		$655K Buy
6,945
+219
+3% +$21.4K ﹤0.01% 1240
2023
Q1 		$680K Sell
6,726
-295
-4% -$30.7K ﹤0.01% 1220
2022
Q4 		$838K Sell
7,021
-59
-0.8% -$6.91K ﹤0.01% 1079
2022
Q3 		$751K Sell
7,080
-149
-2% -$15.1K ﹤0.01% 1113
2022
Q2 		$703K Sell
7,229
-5,313
-42% -$490K ﹤0.01% 1123
2022
Q1 		$1.18M Sell
12,542
-199
-2% -$16.9K 0.01% 1000
2021
Q4 		$1.08M Sell
12,741
-8,680
-41% -$798K 0.01% 1028
2021
Q3 		$2.05M Sell
21,421
-599,300
-97% -$56.6M 0.01% 738
2021
Q2 		$60.4M Sell
620,721
-2,176
-0.3% -$209K 0.34% 63
2021
Q1 		$60.6M Buy
622,897
+16,005
+3% +$1.68M 0.41% 49
2020
Q4 		$58.2M Buy
606,892
+273,732
+82% +$26.4M 0.44% 45
2020
Q3 		$32M Buy
333,160
+259
+0.1% +$30K 0.3% 82
2020
Q2 		$40.6M Buy
332,901
+20,607
+7% +$2.28M 0.43% 49
2020
Q1 		$27M Sell
312,294
-10,161
-3% -$994K 0.35% 58
2019
Q4 		$34.7M Sell
322,455
-28,925
-8% -$3.03M 0.43% 48
2019
Q3 		$31.7M Sell
351,380
-13,391
-4% -$1.25M 0.43% 52
2019
Q2 		$30.8M Buy
364,771
+139,794
+62% +$11.5M 0.43% 56
2019
Q1 		$19.8M Buy
224,977
+221,302
+6,022% +$18.5M 0.28% 81
2018
Q4 		$262K Hold
3,675
– – ﹤0.01% 384
2018
Q3 		$452K Hold
3,675
– – 0.01% 290
2018
Q2 		$361K Hold
3,675
– – 0.01% 295
2018
Q1 		$305K Buy
+3,675
New +$310K 0.01% 302

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rockefeller Capital Management's NBIX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Neurocrine Biosciences (NBIX) stake by 0.28% in Q1 2026, buying an estimated $103K and bringing the position to 282,097 shares worth $37.2M. The position accounts for 0.07% of the portfolio, ranked #280.

Rockefeller Capital Management first reported a position in NBIX in Q1 2018 and has held it in 30 quarters since. The position peaked at $60.6M in Q1 2021. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Rockefeller Capital Management held 282,097 shares of Neurocrine Biosciences worth $37.2M as of Q1 2026.
  • Rockefeller Capital Management bought 777 Neurocrine Biosciences shares in Q1 2026, an estimated $103K.
  • Neurocrine Biosciences made up 0.07% of Rockefeller Capital Management's portfolio in Q1 2026, its #280 holding.
  • Rockefeller Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 30 quarters since.
  • Rockefeller Capital Management's Neurocrine Biosciences position peaked at $60.6M in Q1 2021.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.